1. As of noon trading, Covidien ( COV) is up $0.38 (0.6%) to $61.52 on average volume. Thus far, 1.3 million shares of Covidien exchanged hands as compared to its average daily volume of 2.5 million shares. The stock has ranged in price between $60.99-$61.68 after having opened the day at $61.38 as compared to the previous trading day's close of $61.14.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $27.9 billion and is part of the health care sector. Shares are up 5.2% year to date as of the close of trading on Monday. Currently there are 13 analysts that rate Covidien a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, largely solid financial position with reasonable debt levels by most measures, notable return on equity and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Covidien Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).
null

If you liked this article you might like

PerkinElmer Takes Cautious Approach to M&A

Here's How Health-Care Reform Will Affect This Cancer Care Company

Corporate Tax Reform Could Be a Bigger Deal for This Company Than the ACA

Here Are the Biotech Stocks Moving Ahead of the Opening Bell

PerkinElmer Medical Imaging Unit Sale Could Be in the Works